Introduction
Protective immunity to mycobacteria involves T helper type 1 (Th1) cells, which are under the control of other T cell subsets [1] [2] [3] [4] [5] [6] [7] . Polarized Th1 cells produce interferon (IFN)-g and tumour necrosis factor (TNF)-a in response to mycobacterial antigens, which are critical for macrophage activation and control of bacterial replication [8] .
Cross-talk between various T cell subsets and antigenpresenting cells (APC) is important for induction of the T cell response. Indeed, the interaction of co-stimulatory and co-inhibitory receptors [e.g. CD28, cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1)] expressed on T cells with their respective ligands (e.g. B7-1/ B7-2 and PD-L1/PD-L2) on APC influences the quality and magnitude of the antigen-reactive T cell response [9] . Diverse mechanisms are known to suppress host immunity among pulmonary tuberculosis (PTB) patients [10, 11] . Previously, we have shown that interleukin (IL)210 mediates suppression of the T cell response by regulatory T cells (T reg ) among miliary tuberculosis (MTB) patients [12] . Recent studies indicate the importance of the PD-1-PD-L pathway in infection, autoimmunity and transplant rejection [13, 14] . Several studies indicate that pathogenic microbes exploit the PD-1-PD-L pathway as a strategy for immune evasion and persistent infection. For example, PD-1 is expressed highly on functionally impaired (exhausted) T cells in chronic infection with HIV [15] [16] [17] [18] and SIV [19, 20] . Helicobacter pylori suppresses the T cell response by up-regulating PD-L1 expression on gastric epithelial cells that are thought to act as APC [21, 22] . Recently, we have demonstrated that the co-inhibitory receptor PD-1 and the PD-1 ligands are expressed on a higher percentage of peripheral blood mononuclear cells (PBMCs) of patients with active tuberculosis. Of particular interest, live infection with the M. tuberculosis H37Rv strain up-regulates PD-L1 expression selectively on monocytes [23] . PD-1-blocking in vitro enhances IFN-g and IL-2 production by M. tuberculosis-specific T cells via regulating their apoptosis and proliferation. In-vitro blockade of the PD-1 signalling enhances cytokine production and proliferation by T and natural killer (NK) T cells on M. tuberculosis antigen stimulation [23] [24] [25] [26] , suggesting that the PD-1-PD-L pathway may play an important role in selective suppression of the Th1 response at the pathological site in MTB. This may result in a Th2-dominant effector immune response, thus causing bacillary dissemination characterized by haematogenous spread of the bacilli, thus giving rise to progressive and disseminated form(s) of diseases such as MTB.
Previously we have shown that inhibiting the PD-1 pathway rescues M. tuberculosis-specific IFN-g-producing T cells from apoptosis in PTB patients, and the number of PD-1-expressing T cells decreased significantly during therapy and correlated inversely with the IFN-g dominant T cell response against M. tuberculosis [23] . In this study, we evaluated the regulation and immune function of PD-1-PD-L1 pathways at the pathological site of MTB and tuberculosis pleural effusion (TB-PE). Perhaps, for the first time, we have demonstrated a profound increase in PD-1 1 T cells and PD-L1/PD-L2-expressing monocytes at the pathological site of MTB patients. Of note, we found that the PD-1 pathway selectively inhibits M. tuberculosis-specific TNF-a, IFN-g and IL-2-producing multi-functional T cells at the pathological site of MTB with greater magnitude than that of peripheral blood (PB) and TB-PE cells.
Material and methods

Subjects
The study included 27 patients with TB [13 MTB (mean age 33 6 12Á6 years, range 17-52; 10 males and three females) and 14 TB-PE (mean age 29Á9 6 11Á2 years, range 18-50; 11 males and three females)] attending the All India Institute of Medical Sciences Hospital, New Delhi, India for treatment. Twenty three healthy controls (HCs) (mean age 27Á53 6 8Á69, range 23-48 with 15 males and eight females) with no diagnosed ailments, normal blood parameters and chest radiographs were also recruited. Written informed consent was obtained from all study subjects. The Institutional Ethics Committee (Ref. no. A-60:/ 25.07.2007, dated 28 August 2008) approved the study. Diagnosis of MTB was made according to the previously described criteria [12, 27] . Details of the diagnostic workup are provided in Table 1 . Diagnosis of patients with TB-PE was based on the parameters shown in Table 1 , with presence of fluid in chest radiograph (postero-anterior view). All subjects were HIV-negative. PB (8-12 ml) was collected from all the subjects. Pleural effusion fluid (PEF) was collected from patients with TB-PE, whereas bronchoalveolar lavage (BAL) fluid was collected from patients with MTB as local disease site specimens (LDSS), as per our previously described protocol [12] and Supporting information, Fig. S1 . None of the patients was on anti-TB treatment at the time of enrolment into the study.
Cell isolation and flow cytometry
PBMCs were isolated from heparinized blood by Ficoll Hypaque gradient centrifugation and suspended in complete RPMI-1640 (Caisson Laboratories, Logan, UT, USA). Cells were harvested from PEF and BAL by methods described previously [12] . The viability of the cells was greater than 98% (Trypan blue dye exclusion). Cells were used for surface phenotyping using a-CD3, a-CD14, a-CD19 (BD Biosciences, San Jose, CA, USA), a-PD-1, a-PD-L1 and a-PD-L2 antibodies (eBiosciences, San Diego, CA, USA), and were run on a BD fluorescence activated cell sorter (FACS)Calibur (BD Biosciences) and analysed subsequently by Flow-Jo software (TreeStar Inc., Ashland, OR, USA).
In-vitro cell culture and PD-1-PD-L1 blocking
Freshly isolated PBMCs were incubated with or without blocking antibodies against PD-1 (5 lg/ml, J116; eBiosciences) using a-PD-L1, a-PD-L2 (5 lg/ml, MIH1; eBiosciences), as described previously [23, 24] and Supporting information, Fig. S2 , in the presence or absence of M. tuberculosis (20 lg/ml, whole cell lysate) for 72 h and brefeldin A (GolgiPLUG 10 mg/ml; Sigma, St Louis, MO, USA) for last 12 h of culture. Purified mouse immunoglobulin (Ig)G1 (final concentration of 10 lg/ ml; eBiosciences) was used as an isotype control. Cultured cells were stained with the LIVE/DEAD fixable dead cell stain kit (Invitrogen, Carlsbad, CA, USA). Cells were stained subsequently with a-CD3, a-CD4 (BD Biosciences) followed by intracellular detection of IFN-g, TNF-a, IL-2 and IL-4 using a-IFN-g, a-TNF-a, a-IL-2 and a-IL-4 antibodies (BD Biosciences). Fixation/permeabilization buffers (eBioscience) were used for intracellular staining. In a separate experiment, the impact of PD-1 blocking on T cells apoptosis (annexin V) was measured as described elsewhere [24, 28] . Briefly, for apoptosis study of T cells, annexin V-fluorescein isothiocyanate (FITC) (cat. no. 556420; BD Biosciences) staining was performed before fixation at room temperature, as per the manufacturer's instructions. Finally, cells were stained with a-CD3 (BD Biosciences). Propidium iodide was added 15 min prior to acquisition of the sample. Stained cells were then acquired on a BD FACSCanto II equipped with Diva software and analysed using Flow-Jo software (TreeStar Inc.). The gating strategy in this study is shown in Supporting information, Fig. S3 ).
Statistical analysis
Statistical analysis was performed using the nonparametric Mann-Whitney test for unpaired samples and the Wilcoxon rank-sum test for paired samples. Values of P 0Á05 were considered significant, but * denotes P 0Á05 and ** denotes P 0Á005.
Results
PD-1 and its ligand(s) (PD-L1 and PD-L2) expression on T cells of TB-PE and miliary TB patients
We evaluated the expression of PD-1 receptor and its ligand(s) on T and B cells and monocytes, both in immune-reactive TB-PE and MTB patients (disseminated form of tuberculosis). Flow cytometry was performed on MNCs of PB, PEF and BAL with the aim of evaluating the relevance of PD-1 and its ligand(s) in suppression of the host effector T cell response at the pathological site. The frequency of PD-1 1 T cells was significantly higher (54Á2 6 27Á4 versus 15Á6 6 9Á2, P 5 0Á0002) at the disease site of MTB patients (BAL) compared to their peripheral compartment and with PB of HCs (9Á74 6 4Á3, Fig. 1a,b) . However, a similar enrichment of PD-1 1 T cells in the PE of TB-PE patients relative to their PB was not observed, although it was increased significantly (28Á8 6 13Á1 versus 18Á2 6 8Á2, P 5 0Á0039). Our results concerning PD-1 ligand expression on T cells show a significantly higher frequency of peripheral PD-1 ligand(s)-expressing T cells among both types of TB patients compared to that of HCs (Fig. 1c,d ). We observed a substantial increase in the frequencies of these cells both in the PB and LDSS of TB-PE and MTB patients. The frequency of PD-1 1 T cells was increased significantly in the PB of both TB-PE and MTB patients compared to that of HCs, suggesting the possible role of PD-1 expression of T cells in tuberculosis patients [23] . However, their enrichment was profound in the BAL of MTB patients compared to that of PEF of TB-PE patients. This further suggests the relevance of PD-1 expression of T cells at the LDSS of MTB patients. A similar observation was noted with respect to PD-L1 and PD-L2 expression of the locally accumulated T cells among MTB patients. No difference was observed between ligand(s)-expressing T cells in the MNCs of PB and PE of TB-PE patients ( PB as well as PE of TB-PE (PB; 37Á7 6 18Á2, PE; 28Á5 6 9Á7 versus 3 6 2Á3, P 5 0Á0001) and PB and BAL of MTB patients (PB; 28Á5 6 15Á5, BAL; 40Á2 6 20Á1 versus 3 6 2Á3, P 5 0Á0023). A similar observation was noted for PD-L2, although the magnitude of expression was much lower ( Blocking PD-1-PD-L1 interaction augments M. tuberculosis-specific IFN-g, TNF-a and IL-2 production by CD3
T cells from TB patients
Previously, we have demonstrated that patients with TB-PE had significantly higher IFN-g levels in their PF compared with that of PB of the same patients, thus exhibiting localization of a predominantly Th1-type immunity in the PF. Conversely, patients with MTB had higher IFN-g levels in the PB compared to their BAL fluid, suggesting that the cytokine profile at the disease site is skewed towards a Th2-like bias [29] . To verify possible PD-1-mediated inhibition of Th1-response antigen-specific CD4 1 T cells of the local disease site of MTB, we compared the ability of CD4 1 T cells to produce IFN-g, TNF-a, IL-2 and IL-4 in the presence or absence of PD-1 blocking.
In-vitro blocking of PD-1 and PD-L1/2 increased the frequency of M. tuberculosis-specific IFN-g-producing T cells both in PB as well as in LDSS, including TB-PE and MTB. In general, blocking the PD-1 pathway rescued M. tuberculosisspecific IFN-g producers both in TB-PE and MTB, substantiating our previous observation that inhibiting the PD-1 pathway restores antigen-specific IFN-g-producing T and NK T cells among PTB patients [23, 24] . However, the increase of antigen-specific IFN-g-producing T cells following PD-1 blocking was maximal in BAL-derived T cells from MTB patients (more than sixfold, or 600% rescue in BAL compared to 30% rescue in PB of MTB) compared to PB of TB-PE and HCs, suggesting the highest degree of PD-1-mediated suppression of IFN-g-producing effector T cells in the pathological site of MTB (Fig. 3a,b) . Conversely, in the case of TB-PE, the increase in antigen-specific IFN-g 1 producers in PE- derived T cells after blocking the PD-1-PD-L1 pathway was just double, or 100% (Fig. 3a,b) . Interestingly, PD-1 pathway-blocking failed to show any significant impact on the frequency of M. tuberculosis-specific IL-4-producing T cells derived from both PB and LDSS of TB-PE and MTB patients, respectively (Fig. 3c,d ). Taken together, our results clearly suggest maximum inhibition of IFN-g producers in the pathological site sparing the IL-4 producers, thus skewing the local immune response of MTB patients towards IL-4 dominance. The recently appreciated important role of polyfunctional T cells producing multiple cytokines at single-cell level prompted us to determine if PD-1 blocked rescue of the antigen-specific polyfunctional T cells in the BAL of MTB patients. We observed that, along with the increase in the single cytokine producers, PD-1 inhibition increased the frequency of M. tuberculosis-specific single or dual cytokine producers (IFN-g ) and rescue of these polyfunctional T cells was significantly higher in the BAL of MTB patients (Fig. 4a,b,c) . In addition to dual cytokine producers, PD-1 blocking profoundly enhances the frequency of single TNF-a-producing CD4 T cells (approximately 600%) followed by single IFN-g 1 CD4 T
cells (approximately 400%) in BAL of MTB compared to its PB counterpart. This indicates that, in addition to suppressing the single IFN-g and TNF-a producers, PD-1 inhibits the polyfunctional T cells significantly more in the pathological site of MTB, which is believed to be critical for host immunity.
Inhibition of T cell apoptosis upon blocking PD-1-PD-L1/L2 interaction
Further, to test the effect of blocking PD-1-PD-L1/L2 interactions on T cell apoptosis, we evaluated M. A. Singh et al.
tuberculosis antigen-induced CD3 1 T cell apoptosis using flow cytometry-based annexin V and propidium iodide staining, as described elsewhere [24, 28] . We observed a significant reduction of both early (annexin 1 PI -) and late
) apoptotic M. tuberculosis-specific T cells in PB as well as BAL of MTB patients after PD-1 blocking. However, the reduction of apoptosis following blocked PD-1 was significantly higher in the BAL-derived T cells over that of PB (Fig. 5a,b ). This indicates that over-expression of PD-1 in the local pathological milieu of tuberculosis leads to higher induction of apoptosis of effector T cells in the lung of MTB patients.
Discussion
M. tuberculosis infection is contained by intense granulomatous inflammation at the pathological site through orchestrated generation and localization of Th1 effector cells, as observed in TB-PE, a localized form of disease. Conversely, the suppressed state of local immunity fails to contain the infection, leading to development of progressive and disseminated disease such as MTB [29] . We and others have demonstrated that local immune response in tuberculosis is determined by the proportional presence of effector and T reg cells in the milieu and this, in turn, dictates the form of disease development [12, [30] [31] [32] . The mechanism(s) underlying this delicate balance of local immune response still remains incompletely understood. Therefore, it is important to understand the regulatory mechanisms regulating the type and magnitude of immune response elicited at the pathological site of TB. Recent studies demonstrate that PD-1 regulates T cell activation, peripheral tolerance and autoimmunity, principally as an inhibitory molecule [9, 33, 34] . Several studies have demonstrated that the PD-1 signalling pathway is activated during persistent infection with various microorganisms and contributes to impairment of protective immunity [25, 26] . We have shown recently that in-vitro blockade of PD-1 signalling enhanced M. tuberculosis-specific IFN-g production by T cells [23] and NK T cells of PTB patients [24] , indicating that this inhibitory pathway also affects the T cell functions during mycobacterial infection. In the present study, we investi- Mycobacterial infections are controlled mainly by an activation of macrophages through type 1 cytokine production by T cells, and IFN-g is central to this process [35] . Therefore, production of IFN-g and a shift towards a Th1 cytokine profile are crucial mediators in protection against M. tuberculosis [1] . Previously, we showed that patients with TB-PE have a predominantly Th1 cytokine (IFN-g), whereas the lungs of patients with MTB have a relative enrichment with the Th2 cytokine (IL-4) [29, 36] . Considering the plausible involvement of PD-1 pathway in dampening host immunity among MTB patients, in this study we evaluated the impact of the PD-1 pathway on the effector T cells infiltrated in the lung of MTB patients. In our study, blocking the PD-1 pathway resulted in the most profound rescue of IFN-g 1 and TNF-a T cells obtained from the BAL relative to the rescue of that obtained from PB of MTB patients. However, inhibition of the PD-1 pathway failed to rescue IL-4 producers T cells both in BAL and PB. These findings, coupled with increased expression of PD-1 and its ligands, indicates strongly that in the local milieu of MTB, PD-1 dampens the IFN-g 1 and TNF-a T cells dominantly and preferentially, while sparing the IL-4 producers (Fig. 3a-d, Fig. 4a-c) . We also show that the PD-1 pathway induces apoptosis and death of T cells more profoundly in the lung of MTB patients.Thus, at the local disease site of MTB, PD-1 selectively inhibits the protective M. tuberculosis-specific T cells while sparing the suppressive IL-4 producers, thereby shifting the local immune functions towards a more deficient state. This plausibly disrupts the protective Th1 response and skews the host immunity towards a suppressed state, and leads to the failure of eliciting an adequate level of effector immunity at the pathological site of MTB. Previously, we have demonstrated that T reg cells could suppress peripheral M. tuberculosis-specific T cells via the PD-1 pathway [23] . In the present study, we report a similar but more profound role of this pathway in the lung of MTB patients. In other words, our results indicate the potential use of the PD-1 pathway in rescuing the relevant specific host immunity in the pathological milieu of disseminated forms of tuberculosis such as MTB. Interestingly, we observed that inhibiting the PD-1 pathway could significantly rescue polyfunctional T cells (IFNg 1 TNF-a 1 and IFN-g 1 IL- 2 1 ) in the BAL of MTB patients (Fig. 4a-c) . Recent evidence suggests strongly the critical role of polyfunctional or 'quality' T cells in containing tuberculosis [37, 38] . Studies have shown that the diverse cytokine production profile of T cells shifts towards dominant single cytokine production by M. tuberculosisspecific T cells among TB patients [39] . Interestingly, in our blocking experiment we found that single TNF-a producer CD4 T cells are dominant over other single cytokines (TNF-a 1 , IFN-g 1 and IL-2 1 ) and dual cytokine (IFNg 1 TNF-a 1 and IFN-g ligands is a mechanism responsible for local immunosuppression leading to disease dissemination.
PD-1 regulates effector T cell activity in peripheral tissues in response to infection or tumour progression [40] . Several recent studies, including ours [15] [16] [17] [18] [19] [20] [21] [22] , shows that during chronic infection PD-1 is over-expressed on exhausted T cells and blocking the PD-1-PD-L1 pathway restores proliferation, cytokine secretion and cytotoxicity, suggesting that PD-1-mediated suppression of host immunity plays an important role in tuberculosis [23] [24] [25] [26] . However, studies on PD-1 knock-out mice demonstrated reduced survival of mice infected with M. tuberculosis [41] [42] [43] , and a report by Lee et al. showed that tuberculosis reactivation in a patient receiving the anti-programmed death-1 (PD-1) inhibitor used in Hodgkin's lymphoma might indicate homeostatically different roles of PD-1 at different stages of tuberculosis [44] . We believe that such discordance may be due to an aberrantly heightened inflammatory response with excessive neutrophilic infiltration and necrosis elicited in PD-1 knock-out animals, which may exert a lethal influence on their survival [41] . In our opinion, these studies do not rule out the immunosuppressive role of PD-1 in suppression of the host T cell response in humans. We propose that a basal level of PD-1 expression is required to control the excessive inflammatory response following M. tuberculosis infection, as observed among PD-1-deficient mice. Conversely, overexpression of PD-1 on T cells inhibits the protective T cell response against M. tuberculosis; this might lead to failure to contain M. tuberculosis infection despite an exaggerated inflammatory response. Knocking out PD-1 or the excessive use of PD-1 inhibitors may disrupt the physiological homeostatic control of the elicitation of an appropriate T cell response necessary for protection and allowing reactivation of latent TB infection after PD-1 blockade immunotherapy. Therefore, we propose that inhibiting the PD-1 pathway may restore host immunity and thus help in disease containment in active tuberculosis, while the same may disrupt the homeostatic containment of latent tuberculosis, thereby possibly activating the disease.
In recent years, increasing animal and human studies have demonstrated that the PD-1-PD-1 pathway plays an important role in immune response during tuberculosis [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Several of these studies in humans have shown that blockade of this pathway can enhance the Mtb-specific cytokine production, proliferation and lytic activity of CD8 T cells [23] [24] [25] [26] . Moreover, blockade of the PD-1-PD-L1 pathway enhances lytic degranulation of NK cells and IFNg production by NK [26] and NK T [24] A decline in the number of PD-1 1 T cells during chemotherapy has been reported in viral diseases and tuberculosis [23, 24] . A recent study demonstrated increased levels of soluble PD-1, expression of PD-1 and PD-L1 on T cells as well as pleural mesothelial cells of pleura in TB-PE patients. This is in concordance with our present findings in TB-PE and MTB [45] . In the present study we did not have an opportunity to check PD-1 expression in TB-PE and MTB during successful anti-tubercular treatment. However, we have demonstrated previously that effective anti-tubercular treatment results in a significant reduction of PD-1 1 T and NK T cells [23, 24] . Similarly, another recent study has demonstrated such a decline in PD-1, PD-L1 and PD-L2 gene expression during the intensive phase of TB treatment [46] . Overall, the present study demonstrates the potential role of the PD-1 pathway in the impairment of protective immunity, particularly at the disease site, of more disseminated forms of tuberculosis, such as miliary tuberculosis. We propose that blockade of the co-inhibitory PD-1 pathway may be a key to the augmentation of protective T cells, including polyfunctional T cells, at the pathological site, thus abrogating disease dissemination in MTB. It also reinforces the possibility of immune restoration with the possible application of a novel therapy for human tuberculosis. Further studies will help in understanding the detailed inhibitory role of the PD-1 pathway in tuberculosis and the potential application of PD-1 in immunotherapy and vaccination for TB. research work and wrote the manuscript. All authors have scrutinized the manuscript.
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Supporting information
Additional Supporting information may be found in the online version of this article at the publisher's web-site: Fig. S1 . Standardization of cell isolation from bronchoalveolar lavage (BAL) fluid. Cell separation from BAL has been a challenging task due to presence of sticky debris/ carbon particles/mucous/coagulum/fibres, etc., causing cell clumping which prevented the preparation of single cell suspensions required for good flow cytometric analysis. Moreover, it was observed that due to the presence of the above-mentioned debris, the forward (FSC)-versus side-scatter (SSC) profile of the acquired cells obtained from BAL was unconvincing. Therefore, the protocol was modified in the laboratory for improved cell yield. After collection of BAL fluid, it was centrifuged at 4500 g for 10 min followed by washing with phosphate-buffered saline (PBS) and incomplete RPMI-1640. Thereafter, the cells obtained were subjected to filtration through a 40 mm filter to harvest enriched lymphocytes for further fluorescence activated cell sorter (FACS)-based analysis. Finally, cells were suspended in complete RPMI-1640 until further experimentation. It was interesting to note that this additional step of filtration led to the improvement in CD3 1 cells with the use of the 40 mm filter while isolating the cells from BAL of patients with tuberculosis as determined by flow cytometry. As evident by flow cytometry, without filtration, the cell yield of lymphocytes varied generally from 5 to 20%, whereas CD3
1 ranged from 5 to 40% of the total acquired events. Flow cytometry of BAL-derived cells revealed that staining was observed after the filtration improvement in yields of both lymphocytes (ranging from 15 to 40%) and CD3
1 cells (20-60%). 
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1 cells was observed. We found a maximum number of PD-1 1 CD4 1 cells at concentrations of 5 lg and 10 lg per ml of pure PD-1 antibody, which is equal to the percentage of cells obtained from anti-PD-1 FITC antibody. (a,b) Similar results were obtained for pure a-PD-L1 (5 lg/ml) and a-PD-L2 (5 lg/ml) antibodies. Thus, for each pure antibody, a concentration of 5 lg/ml was used for blockade of PD-1-PD-L1/L2 interaction. Dose optimization of pure anti-PD-1 antibody for in-vitro PD-1-PD-L1/L2 blocking experiment: 2 3 10 6 /ml was taken in a Ubottomed culture plate (Falcon, Austin, TX, USA). Varying doses of anti-PD-1 pure antibody (range 0Á5 lg, 1 lg, 2Á5 lg, 5 lg, 10 lg per ml culture) were added in duplicate for each concentration. Cells were incubated at 48C for 45-60 min. Cells were stained with IgGk1 
